Tudor Investment Corp ET AL Takes $3.77 Million Position in Grail, Inc. (NASDAQ:GRAL)

Tudor Investment Corp ET AL purchased a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 211,208 shares of the company's stock, valued at approximately $3,770,000. Tudor Investment Corp ET AL owned 0.63% of Grail as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Douglas Lane & Associates LLC purchased a new stake in shares of Grail during the fourth quarter worth $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new stake in Grail during the 4th quarter worth about $430,000. FNY Investment Advisers LLC acquired a new stake in Grail in the 4th quarter valued at about $26,000. 180 Wealth Advisors LLC purchased a new position in shares of Grail in the 4th quarter valued at about $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management acquired a new position in shares of Grail during the fourth quarter worth about $387,000.

Insider Transactions at Grail

In related news, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.21, for a total transaction of $237,976.25. Following the sale, the chief executive officer now owns 828,662 shares of the company's stock, valued at $25,862,541.02. This trade represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Aaron Freidin sold 1,816 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $31.20, for a total transaction of $56,659.20. Following the completion of the transaction, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at $10,457,304. The trade was a 0.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,550 shares of company stock valued at $360,436 in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GRAL shares. Canaccord Genuity Group started coverage on Grail in a report on Monday, April 21st. They issued a "buy" rating and a $32.00 target price on the stock. Morgan Stanley increased their price objective on Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a report on Tuesday, March 18th.

Grail Stock Up 10.1 %

Shares of GRAL traded up $3.29 during midday trading on Friday, reaching $35.78. 1,689,329 shares of the stock were exchanged, compared to its average volume of 1,226,638. Grail, Inc. has a twelve month low of $12.33 and a twelve month high of $63.99. The business's 50-day moving average price is $30.08 and its 200 day moving average price is $25.08.

Grail (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analysts' expectations of $35.33 million. Analysts anticipate that Grail, Inc. will post -15.15 EPS for the current year.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.